Analysis of Antiangiogenic Potential and Cell Death Mechanism of a Kinetically Inert Platinum Antitumor Agent

Manikandan M1, Sushanta Chhatar1, Saurabh Dey2

  • 1Medicinal Chemistry and Cell Biology Laboratory, Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai, Maharashtra 400005, India.

PubMed

Insights

A novel platinum compound, Pt-1, effectively combats cancer by inhibiting proliferation and angiogenesis while overcoming chemoresistance. It induces cell death via necroptosis and paraptosis with minimal toxicity, showing significant therapeutic promise.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Cancer involves complex processes like proliferation, resistance, and angiogenesis.
  • Existing chemotherapies face challenges with resistance and toxicity.
  • Targeting multiple pathways simultaneously offers a promising therapeutic strategy.

Purpose of the Study:

  • To investigate the antiangiogenic potential of the platinum compound Pt-1.
  • To elucidate the cell death mechanisms underlying Pt-1's antitumor activity.
  • To evaluate Pt-1 as a multifaceted anticancer agent.

Main Methods:

  • In vivo antiangiogenesis assay using a zebrafish model.
  • Cell death pathway analysis (necroptosis and paraptosis).
  • Assessment of Pt-1's efficacy at therapeutically relevant doses.

Main Results:

  • Pt-1 demonstrated significant inhibition of angiogenesis in vivo.
  • Pt-1 induced cancer cell death through both necroptosis and paraptosis.
  • The compound exhibited antitumor activity at non-toxic, therapeutically relevant concentrations.

Conclusions:

  • Pt-1 possesses potent antiangiogenic properties.
  • Pt-1 effectively triggers antitumor responses via specific cell death pathways.
  • The dual action of antitumor and antiangiogenic effects makes Pt-1 a promising candidate for cancer therapy.

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...